Respiratory Medicines · LP-069
Budesonide Nebulizer solution
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-069Respiratory Medicines
- Generic identity
- BudesonideNebulizer solution
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-069
- Generic identity
- Budesonide
- Presentation
- Nebulizer solution
- Catalogue strength
- 0.25 mg/2 mL; 0.5 mg/2 mL
- Catalogue pack
- Unit-dose nebules; carton 20
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Budesonide.
- Dosage form: Nebulizer solution.
- Catalogue strength / concentration: 0.25 mg/2 mL; 0.5 mg/2 mL.
- Catalogue pack: Unit-dose nebules; carton 20.
- Catalogue category: Respiratory Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Exact physical dosage form (solution versus suspension), composition, sterility and single-dose container specification.
- Nebulizer/compressor compatibility, shaking/mixing instructions and after-opening handling.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
External comparator labels demonstrate why solution-versus-suspension terminology matters; they do not change the controlled catalogue field.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 0.25 mg/2 mL | Nebulizer solution — catalogue wording | — | Unit-dose nebules; carton 20; controlled strength-to-nebule SKU evidence not supplied | Do not convert the source wording to inhalation suspension without controlled Luang specification. |
| B | 0.5 mg/2 mL | Nebulizer solution — catalogue wording | — | Unit-dose nebules; carton 20; controlled strength-to-nebule SKU evidence not supplied | Do not convert the source wording to inhalation suspension without controlled Luang specification. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Budesonide is a corticosteroid used in inhaled presentations to control airway inflammation. A single-ingredient inhaler or nebulizer product has a different role from a combination containing a rapid bronchodilator. It should not be assumed to provide immediate rescue relief. This general educational profile does not establish a Luang Pharma approved respiratory indication, the physical state of a nebulizer formulation or equivalence between different delivery devices.
Clinical context and therapeutic role
A clinician selects the presentation within a defined respiratory plan and confirms that the patient or caregiver can use the device correctly. Inhalers and nebulized preparations have different operational requirements; their stated quantities are not direct conversion instructions. Follow-up reviews symptom control, technique and adverse effects. A patient with acute deterioration needs a separate escalation plan. In children, growth and the continuing need for the prescribed exposure may require clinical review.
Selected safety context
Hoarseness, throat irritation and oral thrush may occur. Mouth care and, where relevant, face cleansing after a mask should follow the product and device instructions. Prolonged systemic exposure can affect adrenal function, growth, bone health and eyes. Some strong metabolic inhibitors increase exposure. Immediate worsening of breathing after inhalation requires assessment. Do not use an oral budesonide product in a nebulizer, and do not change other corticosteroid treatment without professional supervision.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue uses the term nebulizer solution. The actual physical form, concentration, fill volume and compatible nebulizer system require confirmation from authorized information. Some medicines in this class are supplied as suspensions, so that distinction must be resolved. Inhalation products are not for injection or swallowing.
Use only the specified compatible nebulizer and follow cleaning and single-use instructions where applicable. Do not mix with other medicines or diluents unless compatibility is explicitly established. Storage and any period after opening an ampoule must come from the exact supplied product.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A respiratory-care professional should verify the diagnosis, inhaled-versus-oral role, exact device and technique where applicable. The patient requires a clear plan for worsening symptoms, with regular review of control and adverse effects.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: Budesonide inhalers — clinical backgroundArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| NHS: Budesonide inhalers — side effectsArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| MedlinePlus: Budesonide oral inhalationArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Budesonide inhalation suspension — external label exampleArchived source classification: US official drug label example | Source revision recorded: Current label crawled 2026; Archived access check: 2026-09-11 | External comparator showing inhalation-suspension terminology and 2 mL unit-dose ampules; not Luang Pharma formulation evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-069.
Professional enquiries
Request product-specific evidence for LP-069.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.